TWI874337B - 神經活性類固醇及其使用方法 - Google Patents
神經活性類固醇及其使用方法 Download PDFInfo
- Publication number
- TWI874337B TWI874337B TW108144589A TW108144589A TWI874337B TW I874337 B TWI874337 B TW I874337B TW 108144589 A TW108144589 A TW 108144589A TW 108144589 A TW108144589 A TW 108144589A TW I874337 B TWI874337 B TW I874337B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- substituted
- unsubstituted
- group
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862775470P | 2018-12-05 | 2018-12-05 | |
| US62/775,470 | 2018-12-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202039528A TW202039528A (zh) | 2020-11-01 |
| TWI874337B true TWI874337B (zh) | 2025-03-01 |
Family
ID=69006056
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108144589A TWI874337B (zh) | 2018-12-05 | 2019-12-05 | 神經活性類固醇及其使用方法 |
| TW114104451A TWI924370B (zh) | 2018-12-05 | 2019-12-05 | 神經活性類固醇及其使用方法 |
| TW114104450A TW202521127A (zh) | 2018-12-05 | 2019-12-05 | 神經活性類固醇及其使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW114104451A TWI924370B (zh) | 2018-12-05 | 2019-12-05 | 神經活性類固醇及其使用方法 |
| TW114104450A TW202521127A (zh) | 2018-12-05 | 2019-12-05 | 神經活性類固醇及其使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US20230322846A9 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3902818A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7539378B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250174100A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113383004A (cg-RX-API-DMAC7.html) |
| AR (1) | AR117264A1 (cg-RX-API-DMAC7.html) |
| AU (3) | AU2019392680B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021010996A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3120872A1 (cg-RX-API-DMAC7.html) |
| IL (3) | IL312610B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA54594A (cg-RX-API-DMAC7.html) |
| MX (4) | MX2021006618A (cg-RX-API-DMAC7.html) |
| TW (3) | TWI874337B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020118060A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CA3086299A1 (en) * | 2017-12-22 | 2019-06-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| JP7538040B2 (ja) | 2018-01-12 | 2024-08-21 | セージ セラピューティクス, インコーポレイテッド | CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物 |
| TWI848034B (zh) * | 2018-12-21 | 2024-07-11 | 美商賽吉醫療公司 | 神經活性類固醇及其組合物 |
| JP7670626B2 (ja) * | 2019-05-31 | 2025-04-30 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| JP7787635B2 (ja) * | 2019-06-27 | 2025-12-17 | セージ セラピューティクス, エルエルシー | Cns障害を治療するための組成物及び方法 |
| CA3143545A1 (en) * | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
| AU2021238346A1 (en) | 2020-03-18 | 2022-09-29 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CN112679571A (zh) * | 2020-12-24 | 2021-04-20 | 广西壮族自治区中国科学院广西植物研究所 | 一种罗汉果醇衍生物单体、其制备方法及应用 |
| EP4392432A2 (en) * | 2021-08-25 | 2024-07-03 | Sage Therapeutics, Inc. | Positive nmda-modulating compounds and methods of use thereof |
| CN115974950A (zh) * | 2022-12-23 | 2023-04-18 | 上海彩迩文生化科技有限公司 | 一种3-烷基化的甾体中间体及其制备和应用 |
| CN120936616A (zh) | 2023-03-14 | 2025-11-11 | 库里亚西班牙公司 | 用于制备3α-羟基-3β-烷基类固醇的方法和中间体 |
| WO2024197317A2 (en) * | 2023-03-23 | 2024-09-26 | Emory University | Neurosteroids and prodrugs thereof |
| CN119529013B (zh) * | 2024-11-25 | 2025-11-07 | 湖南新合新生物医药有限公司 | 一种祖拉诺龙中间体的合成方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996016076A1 (en) * | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| WO2017049044A1 (en) * | 2015-09-16 | 2017-03-23 | Bartolucci Giampiero | Ursodeoxycholic acid and brain disorders |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2969M (fr) * | 1963-05-22 | 1964-11-30 | Roussel Uclaf | Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale. |
| ES432106A1 (es) | 1973-11-30 | 1976-11-01 | Schering Ag | Procedimiento para la preparacion de d-homo-20-cetopregna- nos. |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4060295A (en) | 1976-03-15 | 1977-11-29 | Molex Incorporated | Zero insertion force printed circuit board edge connector assembly |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
| FR2967914A1 (fr) | 2010-11-29 | 2012-06-01 | Centre Nat Rech Scient | Composes inhibiteurs d'interactions proteine-proteine ciblant les proteines kinases et leurs applications biologiques |
| EP4717314A2 (en) | 2011-10-14 | 2026-04-01 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US9725481B2 (en) * | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| WO2017187343A2 (en) | 2016-04-29 | 2017-11-02 | Thome Kreutz Fernando | Nanoemulsions and methods for cancer therapy |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| EP3728285B1 (en) | 2017-12-22 | 2026-04-08 | Sage Therapeutics, LLC | Compositions and methods for treating cns disorders |
| US20200384003A1 (en) | 2017-12-29 | 2020-12-10 | Shanghai Lanmu Chemicals Co., Ltd. | Triterpenoid-containing pharmaceutical composition and use thereof |
| US12139508B2 (en) | 2018-02-11 | 2024-11-12 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
| JP2022501348A (ja) | 2018-09-19 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | ステロール類似体及びその使用 |
| TWI848034B (zh) | 2018-12-21 | 2024-07-11 | 美商賽吉醫療公司 | 神經活性類固醇及其組合物 |
| WO2020210117A1 (en) | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| WO2020210116A1 (en) | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| US20220226350A1 (en) | 2019-05-30 | 2022-07-21 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| CA3143545A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
| US20220396597A1 (en) | 2019-10-25 | 2022-12-15 | Washington University | Nmdar inhibiting agents and gabaar potentiating agents and uses thereof |
| CN115768781A (zh) | 2020-06-24 | 2023-03-07 | 萨奇治疗股份有限公司 | 3.α.-羟基,17.β.-C(O)-N-芳基取代的神经活性类固醇及其组合物 |
-
2019
- 2019-12-04 IL IL312610A patent/IL312610B2/en unknown
- 2019-12-05 JP JP2021531987A patent/JP7539378B2/ja active Active
- 2019-12-05 TW TW108144589A patent/TWI874337B/zh active
- 2019-12-05 KR KR1020257039569A patent/KR20250174100A/ko active Pending
- 2019-12-05 MX MX2021006618A patent/MX2021006618A/es unknown
- 2019-12-05 MA MA054594A patent/MA54594A/fr unknown
- 2019-12-05 BR BR112021010996-0A patent/BR112021010996A2/pt unknown
- 2019-12-05 KR KR1020217020784A patent/KR102892974B1/ko active Active
- 2019-12-05 CN CN201980091069.0A patent/CN113383004A/zh active Pending
- 2019-12-05 EP EP19828126.3A patent/EP3902818A1/en active Pending
- 2019-12-05 IL IL312611A patent/IL312611B2/en unknown
- 2019-12-05 CA CA3120872A patent/CA3120872A1/en active Pending
- 2019-12-05 IL IL283629A patent/IL283629B2/en unknown
- 2019-12-05 WO PCT/US2019/064692 patent/WO2020118060A1/en not_active Ceased
- 2019-12-05 US US17/311,056 patent/US20230322846A9/en not_active Abandoned
- 2019-12-05 AU AU2019392680A patent/AU2019392680B2/en active Active
- 2019-12-05 TW TW114104451A patent/TWI924370B/zh active
- 2019-12-05 TW TW114104450A patent/TW202521127A/zh unknown
- 2019-12-06 AR ARP190103566A patent/AR117264A1/es unknown
-
2021
- 2021-06-03 MX MX2024004788A patent/MX2024004788A/es unknown
- 2021-06-03 MX MX2024004789A patent/MX2024004789A/es unknown
- 2021-06-03 MX MX2024004790A patent/MX2024004790A/es unknown
-
2023
- 2023-06-13 US US18/334,189 patent/US11999765B2/en active Active
- 2023-06-13 US US18/334,209 patent/US11912738B2/en active Active
- 2023-06-13 US US18/334,124 patent/US11970514B2/en active Active
-
2024
- 2024-03-26 US US18/616,762 patent/US12264177B2/en active Active
- 2024-03-26 US US18/616,903 patent/US12252509B2/en active Active
- 2024-03-26 US US18/616,995 patent/US12410210B2/en active Active
- 2024-05-10 JP JP2024077572A patent/JP7720948B2/ja active Active
-
2025
- 2025-01-14 US US19/019,743 patent/US20250154194A1/en active Pending
- 2025-05-14 AU AU2025203485A patent/AU2025203485A1/en active Pending
- 2025-05-14 AU AU2025203487A patent/AU2025203487A1/en active Pending
- 2025-06-13 JP JP2025099700A patent/JP2025134803A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996016076A1 (en) * | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| WO2017049044A1 (en) * | 2015-09-16 | 2017-03-23 | Bartolucci Giampiero | Ursodeoxycholic acid and brain disorders |
Non-Patent Citations (1)
| Title |
|---|
| 網路文獻 ,Hong-Jin Shu, Lawrence N. Eisenman, Cunde Wang, Achintya K. Bandyopadhyaya,Kathiresan Krishnan, Amanda Taylor, Ann M. Benz, Brad Manion, Alex S. Evers,Douglas F. Covey, Charles F. Zorumski, and Steven Mennerick。 Photodynamic Effects of Steroid-Conjugated Fluorophores on GABAA Receptors Mol Pharmacol 76:754–765, 2009 2009年10月 https://pubmed.ncbi.nlm.nih.gov/19596835/ * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7720948B2 (ja) | 神経刺激性ステロイド及びその使用方法 | |
| JP2025039721A (ja) | 神経刺激性ステロイド及びその組成物 | |
| JP2026021531A (ja) | 神経刺激性ステロイド及びその使用方法 | |
| RU2830163C2 (ru) | Нейроактивные стероиды и способы их применения | |
| EA049422B1 (ru) | Нейроактивные стероиды и их композиции |